Compare CTNM & NML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CTNM | NML |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.0M | 497.5M |
| IPO Year | 2024 | N/A |
| Metric | CTNM | NML |
|---|---|---|
| Price | $13.06 | $10.51 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 331.7K | 182.5K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $7.10 |
| 52 Week High | $16.33 | $10.71 |
| Indicator | CTNM | NML |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 60.50 |
| Support Level | $10.17 | $8.38 |
| Resistance Level | $13.18 | $10.44 |
| Average True Range (ATR) | 1.07 | 0.21 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 42.15 | 55.92 |
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.